733 related articles for article (PubMed ID: 25684107)
1. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
2. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
5. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond.
Orabona C; Grohmann U
Methods Mol Biol; 2011; 677():269-80. PubMed ID: 20941617
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan degradation in patients with gynecological cancer correlates with immune activation.
Schroecksnadel K; Winkler C; Fuith LC; Fuchs D
Cancer Lett; 2005 Jun; 223(2):323-9. PubMed ID: 15896467
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Liu X; Shin N; Koblish HK; Yang G; Wang Q; Wang K; Leffet L; Hansbury MJ; Thomas B; Rupar M; Waeltz P; Bowman KJ; Polam P; Sparks RB; Yue EW; Li Y; Wynn R; Fridman JS; Burn TC; Combs AP; Newton RC; Scherle PA
Blood; 2010 Apr; 115(17):3520-30. PubMed ID: 20197554
[TBL] [Abstract][Full Text] [Related]
9. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression.
Maes M; Leonard BE; Myint AM; Kubera M; Verkerk R
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Apr; 35(3):702-21. PubMed ID: 21185346
[TBL] [Abstract][Full Text] [Related]
10. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
11. Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes.
Solvay M; Holfelder P; Klaessens S; Pilotte L; Stroobant V; Lamy J; Naulaerts S; Spillier Q; Frédérick R; De Plaen E; Sers C; Opitz CA; Van den Eynde BJ; Zhu J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344101
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells.
Curti A; Trabanelli S; Onofri C; Aluigi M; Salvestrini V; Ocadlikova D; Evangelisti C; Rutella S; De Cristofaro R; Ottaviani E; Baccarani M; Lemoli RM
Haematologica; 2010 Dec; 95(12):2022-30. PubMed ID: 20801903
[TBL] [Abstract][Full Text] [Related]
13. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression.
Amobi A; Qian F; Lugade AA; Odunsi K
Adv Exp Med Biol; 2017; 1036():129-144. PubMed ID: 29275469
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers.
Sperner-Unterweger B; Neurauter G; Klieber M; Kurz K; Meraner V; Zeimet A; Fuchs D
Immunobiology; 2011 Mar; 216(3):296-301. PubMed ID: 20822828
[TBL] [Abstract][Full Text] [Related]
15. Targeting tryptophan availability to tumors: the answer to immune escape?
Badawy AA
Immunol Cell Biol; 2018 Nov; 96(10):1026-1034. PubMed ID: 29888434
[TBL] [Abstract][Full Text] [Related]
16. Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone.
Wolowczuk I; Hennart B; Leloire A; Bessede A; Soichot M; Taront S; Caiazzo R; Raverdy V; Pigeyre M; ; Guillemin GJ; Allorge D; Pattou F; Froguel P; Poulain-Godefroy O
Am J Physiol Regul Integr Comp Physiol; 2012 Jul; 303(2):R135-43. PubMed ID: 22592557
[TBL] [Abstract][Full Text] [Related]
17. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
[TBL] [Abstract][Full Text] [Related]
18. Kynurenine pathway metabolism and immune activation: Peripheral measurements in psychiatric and co-morbid conditions.
Strasser B; Becker K; Fuchs D; Gostner JM
Neuropharmacology; 2017 Jan; 112(Pt B):286-296. PubMed ID: 26924709
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
[TBL] [Abstract][Full Text] [Related]
20. Targeting the IDO1 pathway in cancer: from bench to bedside.
Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
